Log in to your Inderes Free account to see all free content on this page.

Demant

213.20 DKK

+0.66 %

Less than 1K followers

DEMANT

NASDAQ Copenhagen

Medical Equipment & Services

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

+0.66 %

-1.93 %

-11.17 %

-16.33 %

-19.30 %

-20.45 %

+3.29 %

-1.48 %

+625.17 %

Demant operates in the medical technology sector. The company specializes in the development of hearing aids and hearing loops. The company operates on a global level where the products are sold under various brands. The products are available through the company's distributors and sales channels. In addition to its main business, the company conducts research in diagnostics for measuring hearing quality. The company was originally founded in 1904 and has its headquarters in Smörum.

Market cap

45.58B DKK

Turnover

40.09M DKK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

3.2.

2026

Annual report '25

5.3.

2026

General meeting '26

11.8.

2026

Interim report Q2'26

All

Press releases

ShowingAll content types

Regulatory press releaseyesterday

Demant A/S: Financial calendar 2026

Regulatory press release12/1/2025, 10:56 AM

Demant A/S: Demant closes the acquisition of KIND

Press release11/19/2025, 11:40 AM

Demant A/S: Investor news - Demant obtains regulatory approval for the acquisition of KIND

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release11/4/2025, 4:04 PM

Demant A/S: Interim Management Statement for Q3 2025

Press release10/22/2025, 6:49 AM

Demant A/S: Investor news - Demant-owned Oticon announces the launch of Oticon Zeal™

Regulatory press release10/21/2025, 11:36 PM

Demant A/S: Demant to sell Oticon Medical to Impilo

Regulatory press release10/9/2025, 3:53 PM

Demant A/S: Niels B. Christiansen, Chair of the Board of Demant, will not stand for re-election

Regulatory press release8/12/2025, 3:47 PM

Demant A/S: Interim Report 2025

Regulatory press release8/12/2025, 3:45 PM

Demant A/S: Revised financial outlook for 2025 and Interim Report 2025

Regulatory press release6/11/2025, 5:00 AM

Demant A/S: Demant to acquire KIND and significantly expand the Group’s hearing care footprint

Regulatory press release5/6/2025, 3:20 PM

Demant A/S: Revised financial outlook for 2025 and Interim Management Statement for Q1 2025

Regulatory press release4/4/2025, 8:05 AM

Demant A/S: Completion of capital reduction

Regulatory press release4/2/2025, 11:43 AM

Demant A/S: Transactions with Demant shares by managers and closely related parties

Regulatory press release3/6/2025, 3:08 PM

Demant A/S: Decisions of annual general meeting

Regulatory press release2/5/2025, 7:10 AM

Demant A/S: Notice of Annual General Meeting

Regulatory press release2/5/2025, 6:32 AM

Demant A/S: Annual Report 2024 and review of H2 2024

Regulatory press release1/10/2025, 8:51 AM

Demant A/S: Transactions with Demant shares by managers and closely related parties

Regulatory press release12/4/2024, 7:28 AM

Demant A/S: Financiel calendar 2025

Regulatory press release11/4/2024, 4:03 PM

Demant A/S: Interim Management Statement for Q3 2024

Regulatory press release9/16/2024, 8:30 AM

Demant A/S: Investor news - New President of Diagnostics and member of Demant Management

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.